|
|
Post by myocat on Apr 19, 2017 8:23:29 GMT -5
|
|
|
|
Post by boytroy88 on Apr 19, 2017 8:29:23 GMT -5
Yeah...I asked that in another thread..he's the managing director at Deerfield.
|
|
|
|
Post by wmdhunt on Apr 19, 2017 9:57:20 GMT -5
www.deerfield.com 17Billion under management. Impressive group of investment analysts, 56 employees, etc. Worldwide reach and scope.
|
|
|
|
Post by porkini on Apr 19, 2017 10:21:19 GMT -5
www.deerfield.com 17Billion under management. Impressive group of investment analysts, 56 employees, etc. Worldwide reach and scope. And then there is the speculation of a buyout not a buyout who would buy and why and how much and on and on and on in various threads. Interesting overview on Deerfield site here: Case Study - CypressSomething to think about. |
|
|
|
Post by wmdhunt on Apr 19, 2017 16:18:22 GMT -5
Very nice Porkini. I am encouraged by this. This is very concise and logical and seems Deerfield is quite adept.
|
|
|
|
Post by kc on Apr 19, 2017 19:00:51 GMT -5
I posted this on the other thread. Maybe he will eventually ask for a board seat and become an activist investor. You can bet that with a 5.1% interest he will want to see a return and perhaps push or help the company to make a sale. I view this all as being positive. Have to do the research on other deals Flynn has been involved in. Deerfield Management, managed by James E. Flynn since 2000, is a healthcare focused investment company that specializes in funding R&D, managing hostile takeovers, corporate transitions and financial advisory services. Deerfield Management oversees $3.5 billion in assets. Read more at www.insidermonkey.com/hedge-fund/deerfield+management/408/#DxSlo4jADmByZ6bp.99Remember Flynn wants to win with MannKind... www.fiercebiotech.com/special-report/deerfield-managementwww.bloomberg.com/research/stocks/private/person.asp?personId=8002481&privcapId=3751585Background Mr. James Edward Flynn, also known as Jim, has been a Partner of Deerfield Management Company, L.P. since February 2000 and serves as its President. Mr. Flynn served as a Managing Director of the equity research department at ING Baring Furman Selz from 1996 to February 2000, a Vice President of Corporate Developmennt at Alpharma Inc., a pharmaceutical company, from 1993 to 1995, and a Senior Vice President of Equity Research at Kidder, Peabody & Co., an investment banking firm from 1988 to 1993. Mr. Flynn was an Equity Analyst of Kidder Peabody Group Inc., Research Division and ING Groep N.V., Research Division. He serves as a Trustee of Mount Sinai Beth Israel. He serves as a Trustee of Continuum Health Partners, Inc., Beth Israel Medical Center and St Luke's-Roosevelt Hospital Center. He serves as a Director of eCaring LLC. Mr. Flynn attended from University of Michigan in Economics, Cellular Biology and Molecular Biology Read more: mnkd.proboards.com/thread/7610/deal-deerfield-convertible-notes-2019?page=5#ixzz4ek8TkSsh |
|
|
|
Post by jpg on Apr 19, 2017 21:06:56 GMT -5
Very nice Porkini. I am encouraged by this. This is very concise and logical and seems Deerfield is quite adept. Encouraged by this? What??? Why? |
|
|
|
Post by bones1026 on Apr 19, 2017 21:40:00 GMT -5
Very nice Porkini. I am encouraged by this. This is very concise and logical and seems Deerfield is quite adept. Encouraged by this? What??? Why? Yea please explain what I'm missing as well |
|
|
|
Post by boytroy88 on Apr 19, 2017 23:23:00 GMT -5
Encouraged by this? What??? Why? Yea please explain what I'm missing as well If you read that short article you'll find that the CEO of that pharma wrote that Deerfield helped them restructure their financing so that they got a better buyout price. |
|
|
|
Post by jpg on Apr 20, 2017 2:21:54 GMT -5
Yea please explain what I'm missing as well If you read that short article you'll find that the CEO of that pharma wrote that Deerfield helped them restructure their financing so that they got a better buyout price. Yes I read the linked article (from the Deerfield website) that not so surprisingly... paints Deerfield as being the good guys. Shocking they would do this on their own website no? As for this applying to MNKDs particular situation: Apples to toasters. And MNKD is kind of toast... |
|
|
|
Post by careful2invest on Apr 20, 2017 7:43:16 GMT -5
If you read that short article you'll find that the CEO of that pharma wrote that Deerfield helped them restructure their financing so that they got a better buyout price. Yes I read the linked article (from the Deerfield website) that not so surprisingly... paints Deerfield as being the good guys. Shocking they would do this on their own website no? As for this applying to MNKDs particular situation: Apples to toasters. And MNKD is kind of toast... Not yet. |
|
|
|
Post by lakon on Apr 20, 2017 9:32:00 GMT -5
But he already sold according to some on this board...we'll see soon...
|
|
|
|
Post by porkini on Apr 21, 2017 16:20:13 GMT -5
Yes I read the linked article (from the Deerfield website) that not so surprisingly... paints Deerfield as being the good guys. Shocking they would do this on their own website no?As for this applying to MNKDs particular situation: Apples to toasters. And MNKD is kind of toast... Not yet. Very shocking - I thought there was an FDA requirement for them to also say 5 bad things too!  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 21, 2017 16:52:45 GMT -5
Yes I read the linked article (from the Deerfield website) that not so surprisingly... paints Deerfield as being the good guys. Shocking they would do this on their own website no? As for this applying to MNKDs particular situation: Apples to toasters. And MNKD is kind of toast... Not yet. NO they are. A lot of you just refuse to believe it. |
|
